ARK Investment Management LLC trimmed its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 24.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,063 shares of the company’s stock after selling 7,424 shares during the quarter. ARK Investment Management LLC’s holdings in Teva Pharmaceutical Industries were worth $497,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in TEVA. Pinnacle Associates Ltd. increased its position in Teva Pharmaceutical Industries by 11.0% in the 2nd quarter. Pinnacle Associates Ltd. now owns 22,862 shares of the company’s stock valued at $556,000 after acquiring an additional 2,272 shares during the period. Daiwa Securities Group Inc. increased its position in Teva Pharmaceutical Industries by 7.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 34,183 shares of the company’s stock valued at $736,000 after acquiring an additional 2,329 shares during the period. HPM Partners LLC increased its position in Teva Pharmaceutical Industries by 25.4% in the 2nd quarter. HPM Partners LLC now owns 14,657 shares of the company’s stock valued at $356,000 after acquiring an additional 2,971 shares during the period. Point View Wealth Management Inc. increased its position in Teva Pharmaceutical Industries by 4.4% in the 2nd quarter. Point View Wealth Management Inc. now owns 71,603 shares of the company’s stock valued at $1,741,000 after acquiring an additional 2,996 shares during the period. Finally, Cornerstone Investment Partners LLC increased its position in Teva Pharmaceutical Industries by 19.6% in the 2nd quarter. Cornerstone Investment Partners LLC now owns 18,300 shares of the company’s stock valued at $445,000 after acquiring an additional 3,000 shares during the period. Institutional investors and hedge funds own 65.37% of the company’s stock.

Several equities analysts have recently issued reports on the company. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 20th. CIBC reiterated a “market perform” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, September 21st. Royal Bank of Canada reiterated a “hold” rating and set a $19.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday, July 31st. Mizuho reiterated a “buy” rating and set a $28.00 price target on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. Finally, Cantor Fitzgerald set a $25.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, July 19th. Three investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average price target of $22.08.

TEVA opened at $23.53 on Wednesday. The firm has a market cap of $23.85 billion, a PE ratio of 5.99, a P/E/G ratio of 7.14 and a beta of 0.77. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $11.49 and a fifty-two week high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.11. The business had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.54 billion. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The company’s revenue was down 19.4% compared to the same quarter last year. During the same period last year, the company posted $1.00 EPS. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.8 earnings per share for the current fiscal year.

In other news, insider Deborah A. Griffin sold 2,376 shares of the firm’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total transaction of $56,334.96. Following the completion of the sale, the insider now directly owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Richard Daniell sold 2,488 shares of the firm’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the sale, the vice president now directly owns 2,488 shares of the company’s stock, valued at $58,940.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,531 shares of company stock valued at $152,749. Corporate insiders own 0.43% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ARK Investment Management LLC Reduces Stake in Teva Pharmaceutical Industries Ltd (TEVA)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2018/11/14/ark-investment-management-llc-reduces-stake-in-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What are defining characteristics of a correction?

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.